Clinical Trial Detail

NCT ID NCT02655822
Title Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corvus Pharmaceuticals, Inc.
Indications

renal cell carcinoma

prostate adenocarcinoma

Therapies

Atezolizumab + CPI-444

CPI-444

Age Groups: senior adult

No variant requirements are available.